Operating Income (Loss) in USD of Aquestive Therapeutics, Inc. from Q2 2017 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Aquestive Therapeutics, Inc. quarterly/annual Operating Income (Loss) history and change rate from Q2 2017 to Q3 2025.
  • Aquestive Therapeutics, Inc. Operating Income (Loss) for the quarter ending 30 Sep 2025 was -$11.5M, a 38.5% decline year-over-year.
  • Aquestive Therapeutics, Inc. Operating Income (Loss) for the twelve months ending 30 Sep 2025 was -$55.8M, a 164% decline year-over-year.
  • Aquestive Therapeutics, Inc. annual Operating Income (Loss) for 2024 was -$30.8M, a 104% decline from 2023.
  • Aquestive Therapeutics, Inc. annual Operating Income (Loss) for 2023 was -$15.1M, a 64.1% increase from 2022.
  • Aquestive Therapeutics, Inc. annual Operating Income (Loss) for 2022 was -$42.1M, a 21.3% decline from 2021.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Change (%)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Change (%)

Aquestive Therapeutics, Inc. Quarterly Operating Income (Loss) (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 -$55.8M -$11.5M -$3.19M -38.5% 01 Jul 2025 30 Sep 2025 10-Q 05 Nov 2025
Q2 2025 -$52.6M -$11.4M -$11.4M -20769% 01 Apr 2025 30 Jun 2025 10-Q 11 Aug 2025
Q1 2025 -$41.2M -$19.4M -$10.4M -116% 01 Jan 2025 31 Mar 2025 10-Q 12 May 2025
Q4 2024 -$30.8M -$13.6M -$9.67M -247% 01 Oct 2024 31 Dec 2024 10-K 05 Mar 2025
Q3 2024 -$21.1M -$8.29M -$5.91M -249% 01 Jul 2024 30 Sep 2024 10-Q 05 Nov 2025
Q2 2024 -$15.2M $55K +$4.26M 01 Apr 2024 30 Jun 2024 10-Q 11 Aug 2025
Q1 2024 -$19.5M -$8.96M -$4.35M -94.5% 01 Jan 2024 31 Mar 2024 10-Q 12 May 2025
Q4 2023 -$15.1M -$3.91M +$6.8M +63.5% 01 Oct 2023 31 Dec 2023 10-K 05 Mar 2025
Q3 2023 -$21.9M -$2.38M +$6.48M +73.2% 01 Jul 2023 30 Sep 2023 10-Q 04 Nov 2024
Q2 2023 -$28.4M -$4.21M +$8.55M +67% 01 Apr 2023 30 Jun 2023 10-Q 06 Aug 2024
Q1 2023 -$36.9M -$4.61M +$5.13M +52.7% 01 Jan 2023 31 Mar 2023 10-Q 07 May 2024
Q4 2022 -$42.1M -$10.7M +$956K +8.19% 01 Oct 2022 31 Dec 2022 10-K 05 Mar 2024
Q3 2022 -$43M -$8.85M -$885K -11.1% 01 Jul 2022 30 Sep 2022 10-Q 06 Nov 2023
Q2 2022 -$42.1M -$12.8M -$6.25M -95.8% 01 Apr 2022 30 Jun 2022 10-Q 07 Aug 2023
Q1 2022 -$35.9M -$9.74M -$1.21M -14.2% 01 Jan 2022 31 Mar 2022 10-Q 02 May 2023
Q4 2021 -$34.7M -$11.7M +$3.98M +25.4% 01 Oct 2021 31 Dec 2021 10-K 31 Mar 2023
Q3 2021 -$38.7M -$7.97M +$5.81M +42.2% 01 Jul 2021 30 Sep 2021 10-Q 01 Nov 2022
Q2 2021 -$44.5M -$6.52M -$6.91M -1750% 01 Apr 2021 30 Jun 2021 10-Q 02 Aug 2022
Q1 2021 -$37.6M -$8.53M +$5.34M +38.5% 01 Jan 2021 31 Mar 2021 10-Q 04 May 2022
Q4 2020 -$42.9M -$15.6M -$5.74M -58% 01 Oct 2020 31 Dec 2020 10-K 08 Mar 2022
Q3 2020 -$37.2M -$13.8M -$2.78M -25.3% 01 Jul 2020 30 Sep 2020 10-Q 02 Nov 2021
Q2 2020 -$34.4M $395K +$19.1M 01 Apr 2020 30 Jun 2020 10-Q 03 Aug 2021
Q1 2020 -$53.5M -$13.9M -$787K -6.02% 01 Jan 2020 31 Mar 2020 10-Q 04 May 2021
Q4 2019 -$52.7M -$9.9M +$2.42M +19.7% 01 Oct 2019 31 Dec 2019 10-K 09 Mar 2021
Q3 2019 -$55.1M -$11M -$1.8M -19.5% 01 Jul 2019 30 Sep 2019 10-Q 04 Nov 2020
Q2 2019 -$53.3M -$18.7M +$14M +42.9% 01 Apr 2019 30 Jun 2019 10-Q 04 Aug 2020
Q1 2019 -$67.3M -$13.1M -$18.4M -346% 01 Jan 2019 31 Mar 2019 10-Q 05 May 2020
Q4 2018 -$48.9M -$12.3M 01 Oct 2018 31 Dec 2018 10-K 11 Mar 2020
Q3 2018 -$9.21M -$19.6M -188% 01 Jul 2018 30 Sep 2018 10-Q 05 Nov 2019
Q2 2018 -$32.7M -$28.6M -706% 01 Apr 2018 30 Jun 2018 10-Q 06 Aug 2019
Q1 2018 $5.31M 01 Jan 2018 31 Mar 2018 10-Q 08 May 2019
Q3 2017 $10.4M 01 Jul 2017 30 Sep 2017 10-Q 06 Nov 2018
Q2 2017 -$4.06M 01 Apr 2017 30 Jun 2017 10-Q 04 Sep 2018

Aquestive Therapeutics, Inc. Annual Operating Income (Loss) (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 -$30.8M -$15.7M -104% 01 Jan 2024 31 Dec 2024 10-K 05 Mar 2025
2023 -$15.1M +$27M +64.1% 01 Jan 2023 31 Dec 2023 10-K 05 Mar 2025
2022 -$42.1M -$7.39M -21.3% 01 Jan 2022 31 Dec 2022 10-K 05 Mar 2024
2021 -$34.7M +$8.21M +19.2% 01 Jan 2021 31 Dec 2021 10-K 31 Mar 2023
2020 -$42.9M +$9.78M +18.6% 01 Jan 2020 31 Dec 2020 10-K 08 Mar 2022
2019 -$52.7M -$3.73M -7.63% 01 Jan 2019 31 Dec 2019 10-K 09 Mar 2021
2018 -$48.9M -$48.8M -43204% 01 Jan 2018 31 Dec 2018 10-K 11 Mar 2020
2017 -$113K 01 Jan 2017 31 Dec 2017 10-K 14 Mar 2019
* An asterisk sign (*) next to the value indicates that the value is likely invalid.